Search

Your search keyword '"Stahl, Michael"' showing total 1,406 results
Start Over Author "Stahl, Michael"
1,406 results on '"Stahl, Michael"'

3. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?

Author

Weiss, Lena, Heinemann, Volker, Fischer, Laura E., Gieseler, Frank, Hoehler, Thomas, Mayerle, Julia, Quietzsch, Detlef, Reinacher-Schick, Anke, Schenk, Michael, Seipelt, Gernot, Siveke, Jens T., Stahl, Michael, Vehling-Kaiser, Ursula, Waldschmidt, Dirk T., Dorman, Klara, Zhang, Danmei, Westphalen, C. Benedikt, von Bergwelt-Baildon, Michael, Boeck, Stefan, and Haas, Michael

Published
2024
Full Text
View/download PDF

6. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study

Author

Krämer, Alwin, Bochtler, Tilmann, Pauli, Chantal, Shiu, Kai-Keen, Cook, Natalie, de Menezes, Juliana Janoski, Pazo-Cid, Roberto A, Losa, Ferran, Robbrecht, Debbie GJ, Tomášek, Jiří, Arslan, Cagatay, Özgüroğlu, Mustafa, Stahl, Michael, Bigot, Frédéric, Kim, Sun Young, Naito, Yoichi, Italiano, Antoine, Chalabi, Nasséra, Durán-Pacheco, Gonzalo, Michaud, Chantal, Scarato, Jeremy, Thomas, Marlene, Ross, Jeffrey S, Moch, Holger, and Mileshkin, Linda

Published
2024
Full Text
View/download PDF

8. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Author

Pouyiourou, Maria, Kraft, Bianca N., Wohlfromm, Timothy, Stahl, Michael, Kubuschok, Boris, Löffler, Harald, Hacker, Ulrich T., Hübner, Gerdt, Weiss, Lena, Bitzer, Michael, Ernst, Thomas, Schütt, Philipp, Hielscher, Thomas, Delorme, Stefan, Kirchner, Martina, Kazdal, Daniel, Ball, Markus, Kluck, Klaus, Stenzinger, Albrecht, Bochtler, Tilmann, and Krämer, Alwin

Published
2023
Full Text
View/download PDF

9. Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)

Author

Lorenzen, Sylvie, Schwarz, Alix, Pauligk, Claudia, Goekkurt, Eray, Stocker, Gertraud, Knorrenschild, Jorge Riera, Illerhaus, Gerald, Dechow, Tobias, Moehler, Markus, Moulin, Jean-Charles, Pink, Daniel, Stahl, Michael, Schaaf, Marina, Goetze, Thorsten Oliver, and Al-Batran, Salah-Eddin

Published
2023
Full Text
View/download PDF

10. Learning Effectiveness and Students' Perceptions in a Flexible Learning Course

Author

Müller, Claude, Stahl, Michael, Alder, Mark, and Müller, Maximilian

Abstract

With flexible learning, students gain access and flexibility with regard to at least one of the following dimensions: time, place, pace, learning style, content, assessment or learning path. Zurich University of Applied Sciences (ZHAW) has launched a new flexible learning study format called FLEX, a blended learning design allowing students to be more flexible as to when and where they study. It reduces classroom learning time, replacing some of it with an e-learning environment for self-study that includes instructional videos. In a pilot phase, we conducted a semi-experimental study on the learning effectiveness of FLEX. Students' perceptions of the new study format FLEX were found to be positive. In addition, the final test results of students in the FLEX programme were similar to those of other students, despite classroom learning time was reduced by about half.

Published
2018

23. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

Author

Hennes, Elke, Lindig, Udo, Geer, Thomas, Stahl, Michael, Senkal, Metin, Südhoff, Thomas, Egger, Matthias, Kahl, Christoph, Große-Thie, Christina, Reiser, Marcel, Mahlmann, Stefan, Fix, Peter, Schulz, Holger, Maschmeyer, Georg, Blau, Wolfgang, Kunzmann, Volker, Siveke, Jens T, Algül, Hana, Goekkurt, Eray, Siegler, Gabriele, Martens, Uwe, Waldschmidt, Dirk, Pelzer, Uwe, Fuchs, Martin, Kullmann, Frank, Boeck, Stefan, Ettrich, Thomas J, Held, Swantje, Keller, Ralph, Klein, Ingo, Germer, Christoph-Thomas, Stein, Hubert, Friess, Helmut, Bahra, Marcus, Jakobs, Ralf, Hartlapp, Ingo, and Heinemann, Volker

Published
2021
Full Text
View/download PDF

26. Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction:A Network Meta-Analysis

Author

Ronellenfitsch, Ulrich, Friedrichs, Juliane, Barbier, Emilie, Bass, Gary A., Burmeister, Bryan, Cunningham, David, Eyck, Ben M., Grilli, Maurizio, Hofheinz, Ralf Dieter, Kieser, Meinhard, Kleeff, Jörg, Klevebro, Fredrik, Langley, Ruth, Lordick, Florian, Lutz, Manfred, Mauer, Murielle, Michalski, Christoph W., Michl, Patrick, Nankivell, Matthew, Nilsson, Magnus, Seide, Svenja, Shah, Manish A., Shi, Qian, Stahl, Michael, Urba, Susan, Van Lanschot, Jan, Vordermark, Dirk, Walsh, Thomas Noel, Ychou, Marc, Proctor, Tanja, Vey, Johannes A., Ronellenfitsch, Ulrich, Friedrichs, Juliane, Barbier, Emilie, Bass, Gary A., Burmeister, Bryan, Cunningham, David, Eyck, Ben M., Grilli, Maurizio, Hofheinz, Ralf Dieter, Kieser, Meinhard, Kleeff, Jörg, Klevebro, Fredrik, Langley, Ruth, Lordick, Florian, Lutz, Manfred, Mauer, Murielle, Michalski, Christoph W., Michl, Patrick, Nankivell, Matthew, Nilsson, Magnus, Seide, Svenja, Shah, Manish A., Shi, Qian, Stahl, Michael, Urba, Susan, Van Lanschot, Jan, Vordermark, Dirk, Walsh, Thomas Noel, Ychou, Marc, Proctor, Tanja, and Vey, Johannes A.

Abstract

Importance: The prognosis of patients with adenocarcinoma of the esophagus and esophagogastric junction (AEG) is poor. From current evidence, it remains unclear to what extent preoperative chemoradiotherapy (CRT) or preoperative and/or perioperative chemotherapy achieve better outcomes than surgery alone. Objective: To assess the association of preoperative CRT and preoperative and/or perioperative chemotherapy in patients with AEG with overall survival and other outcomes. Data Sources:Literature search in PubMed, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, ClinicalTrials.gov, and International Clinical Trials Registry Platform was performed from inception to April 21, 2023. Study Selection: Two blinded reviewers screened for randomized clinical trials comparing preoperative CRT plus surgery with preoperative and/or perioperative chemotherapy plus surgery, 1 intervention with surgery alone, or all 3 treatments. Only data from participants with AEG were included from trials that encompassed mixed histology or gastric cancer. Among 2768 initially identified studies, 17 (0.6%) met the selection criteria. Data Extraction and Synthesis: The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines were followed for extracting data and assessing data quality by 2 independent extractors. A bayesian network meta-analysis was conducted using the 2-stage approach. Main Outcomes and Measures: Overall and disease-free survival, postoperative morbidity, and mortality. Results:The analyses included 2549 patients (2206 [86.5%] male; mean [SD] age, 61.0 [9.4] years) from 17 trials (conducted from 1989-2016). Both preoperative CRT plus surgery (hazard ratio [HR], 0.75 [95% credible interval (CrI), 0.62-0.90]; 3-year difference, 105 deaths per 1000 patients) and preoperativ

Published
2024

27. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO):an open-label, randomised, phase 2 study

Author

Krämer, Alwin, Bochtler, Tilmann, Pauli, Chantal, Shiu, Kai Keen, Cook, Natalie, de Menezes, Juliana Janoski, Pazo-Cid, Roberto A., Losa, Ferran, Robbrecht, Debbie GJ, Tomášek, Jiří, Arslan, Cagatay, Özgüroğlu, Mustafa, Stahl, Michael, Bigot, Frédéric, Kim, Sun Young, Naito, Yoichi, Italiano, Antoine, Chalabi, Nasséra, Durán-Pacheco, Gonzalo, Michaud, Chantal, Scarato, Jeremy, Thomas, Marlene, Ross, Jeffrey S., Moch, Holger, Mileshkin, Linda, Krämer, Alwin, Bochtler, Tilmann, Pauli, Chantal, Shiu, Kai Keen, Cook, Natalie, de Menezes, Juliana Janoski, Pazo-Cid, Roberto A., Losa, Ferran, Robbrecht, Debbie GJ, Tomášek, Jiří, Arslan, Cagatay, Özgüroğlu, Mustafa, Stahl, Michael, Bigot, Frédéric, Kim, Sun Young, Naito, Yoichi, Italiano, Antoine, Chalabi, Nasséra, Durán-Pacheco, Gonzalo, Michaud, Chantal, Scarato, Jeremy, Thomas, Marlene, Ross, Jeffrey S., Moch, Holger, and Mileshkin, Linda

Abstract

Background: Patients with unfavourable subset cancer of unknown primary (CUP) have a poor prognosis when treated with standard platinum-based chemotherapy. Whether first-line treatment guided by comprehensive genomic profiling (CGP) can improve outcomes is unknown. The CUPISCO trial was designed to inform a molecularly guided treatment strategy to improve outcomes over standard platinum-based chemotherapy in patients with newly diagnosed, unfavourable, non-squamous CUP. The aim of the trial was to compare the efficacy and safety of molecularly guided therapy (MGT) versus standard platinum-based chemotherapy in these patients. This was to determine whether the inclusion of CGP in the initial diagnostic work-up leads to improved outcomes over the current standard of care. We herein report the primary analysis. Methods: CUPISCO was a phase 2, prospective, randomised, open-label, active-controlled, multicentre trial done at 159 sites in 34 countries outside the USA. Patients with central eligibility review-confirmed disease (acceptable histologies included adenocarcinoma and poorly differentiated carcinoma) and an Eastern Cooperative Oncology Group performance status of 0 or 1, evaluated by CGP, who reached disease control after three cycles of standard first-line platinum-based chemotherapy were randomly assigned 3:1 via a block-stratified randomisation procedure to MGT versus chemotherapy continuation for at least three further cycles. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT03498521, and follow-up is ongoing. Findings: From July 10, 2018, to Dec 9, 2022, 636 (42%) of 1505 screened patients were enrolled. Median follow-up in the treatment period was 24·1 months (IQR 11·6–35·6). Of 438 patients who reached disease control after induction chemotherapy, 436 were randomly assigned: 326 (75%) to the MGT group and 110 (25%) to the chemotherapy group.

Published
2024

28. Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma

Author

Thuss-Patience, Peter, primary, Högner, Anica, additional, Goekkurt, Eray, additional, Stahl, Michael, additional, Kretzschmar, Albrecht, additional, Götze, Thorsten, additional, Stocker, Gertraud, additional, Reichardt, Peter, additional, Kullmann, Frank, additional, Pink, Daniel, additional, Bartels, Prisca, additional, Jarosch, Armin, additional, Hinke, Axel, additional, Schultheiß, Christoph, additional, Paschold, Lisa, additional, Stein, Alexander, additional, and Binder, Mascha, additional

Published
2024
Full Text
View/download PDF

30. RAMIRIS: Wirksamkeit von Ramucirumab plus FOLFIRI vs. Ramucirumab plus Paclitaxel bei Patienten mit fortgeschrittenem oder metastasiertem Adenokarzinom des Magens oder des gastroösophagealen Übergangs, die auf eine Erstlinientherapie progredient sind – eine randomisierte Phase-II/III-Studie der AIO

Author

Lorenzen, Sylvie, Goetze, Thorsten O, Dechow, Tobias, Goekkurt, Eray, Hofheinz, Ralf-Dieter, Möhler, Markus, Stahl, Michael, Thuss-Patience, Peter, Hinke, Axel, Herzer, Sascha, Pauligk, Claudia, and Al-Batran, Salah-Eddin

Published
2020
Full Text
View/download PDF

31. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801)

Author

Stahl, Michael, Maderer, Annett, Lordick, Florian, Mihaljevic, Andre L., Kanzler, Stefan, Hoehler, Thomas, Thuss-Patience, Peter, Mönig, Stefan, Kunzmann, Volker, Schroll, Sebastian, Sandermann, Andreas, Tannapfel, Andrea, Meyer, Hans-Joachim, Schuhmacher, Christoph, Wilke, Hansjochen, and Moehler, Markus

Published
2018
Full Text
View/download PDF

32. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?

Author

Weiss, Lena, primary, Heinemann, Volker, additional, Fischer, Laura E., additional, Gieseler, Frank, additional, Hoehler, Thomas, additional, Mayerle, Julia, additional, Quietzsch, Detlef, additional, Reinacher-Schick, Anke, additional, Schenk, Michael, additional, Seipelt, Gernot, additional, Siveke, Jens T., additional, Stahl, Michael, additional, Vehling-Kaiser, Ursula, additional, Waldschmidt, Dirk T., additional, Dorman, Klara, additional, Zhang, Danmei, additional, Westphalen, C. Benedikt, additional, von Bergwelt-Baildon, Michael, additional, Boeck, Stefan, additional, and Haas, Michael, additional

Published
2023
Full Text
View/download PDF

33. The heavenly road.

Author

Stahl, Michael

Subjects
BICYCLE touring, BMW motorcycle, MOTORCYCLE touring, MOUNTAIN biking, TRAIL bikes
Abstract

The article from Vacations & Travel explores the author's motorcycling journey through northern Thailand, highlighting the unique experience of riding on some of the world's most revered roads. The adventure focuses on the camaraderie among fellow riders, the scenic beauty of the landscape, and the cultural experiences along the way. The tour, organized by Big Bike Tours, offers a ready-to-ride adventure for motorcycle enthusiasts, showcasing the Mae Hong Son Loop and other iconic destinations in Thailand. The author's narrative captures the essence of motorcycling mysticism, culinary delights, and the transcendental experience of exploring Thailand on two wheels. [Extracted from the article]

Published
2024

34. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

Author

Thaler, Josef, Greil, Richard, Gaenzer, Johannes, Eisterer, Wolfgang, Tschmelitsch, Joerg, Keil, Felix, Samonigg, Hellmut, Zabernigg, August, Schmid, Franz, Steger, Günther, Steinacher, Robert, Andel, Johannes, Jagdt, Björn, Lang, Alois, Fridrik, Michael, Függer, Reinhold, Hofbauer, Friedrich, Woell, Ewald, Geissler, Dietmar, Lenauer, Alfred, Prager, Manfred, D'Haens, Geert, Demolin, Gauthier, Kerger, Joseph, Deboever, Guido, Ghillebert, Gilbert, Polus, Marc, Van Cutsem, Eric, Kalantari, Hassan Rezaie, Delaunoit, Thierry, Goeminne, Jean Charles, Peeters, Marc, Vergauwe, Philippe, Houbiers, Ghislain, Humblet, Yves, Janssens, Jos, Schrijvers, Dirk, Vanderstraeten, Erik, Van Laethem, Jean-Luc, Vermorken, Jan, Van Daele, Daniel, Ferrante, Michel, Forget, Frederic, Hendlisz, Alain, Yilmaz, Mette, Nielsen, Svend Erik, Vestermark, Lene, Larsen, Jim, Zawadi, Mohamed-Ayman, Bouche, Olivier, Mineur, Laurent, Bennouna-Louridi, Jaafar, Dourthe, Louis Marie, Ychou, Marc, Boucher, Eveline, Taieb, Julien, Pezet, Denis, Desseigne, Francoise, Ducreux, Michel, Texereau, Patrick, Miglianico, Laurent, Rougier, Philippe, Fratte, Serge, Levache, Charles-Briac, Merrouche, Yacine, Ellis, Stephen, Locher, Christophe, Ramee, Jean-Francois, Garnier, Claire, Viret, Frederic, Chauffert, Bruno, Cojean-Zelek, Isabelle, Michel, Pierre, Lecaille, Cedric, Borel, Christian, Seitz, Jean-Francois, Smith, Denis, Lombard-Bohas, Catherine, Andre, Thierry, Gornet, Jean-Marc, Fein, Francine, Coulon-Sfairi, Marie-Aude, Kaminsky, Marie-Christine, Lagasse, Jean-Paul, Luet, Dominique, Etienne, Pierre-Luc, Gasmi, Mohamed, Vanoli, Andre, Nguyen, Suzanne, Aparicio, Thomas, Perrier, Hervé, Stremsdoerfer, Noel, Laplaige, Philippe, Arsene, Dominique, Auby, Dominique, Bedenne, Laurent, Coriat, Romain, Denis, Bernard, Geoffroy, Patrick, Piot, Gilles, Becouarn, Yves, Bordes, Gilbert, Deplanque, Gael, Dupuis, Olivier, Fruge, Frederic, Guimbaud, Rosine, Lecomte, Thierry, Lledo, Gérard, Sobhani, Iradej, Asnacios, Amani, Azzedine, Ahmed, Desauw, Christophe, Galais, Marie-Pierre, Gargot, Dany, Lam, You-Heng, Abakar-Mahamat, Abakar, Berdah, Jean-Francois, Catteau, Sylviane, Clavero-Fabri, Marie-Christine, Codoul, Jean-Francois, Legoux, Jean-Louis, Goldfain, Denis, Guichard, Pierre, Verge, Denis Pere, Provencal, Jocelyne, Vedrenne, Bruno, Brezault-Bonnet, Catherine, Cleau, Denis, Desir, Jean-Paul, Fallik, David, Garcia, Bruno, Gaspard, Marie-Hélène, Genet, Dominique, Hartwig, Johannes, Krummel, Yves, Budnik, Tamara Matysiak, Palascak-Juif, Vanessa, Randrianarivelo, Harizo, Rinaldi, Yves, Aleba, Albert, Darut-Jouve, Ariane, de Gramont, Aimery, Hamon, Herve, Wendehenne, Frederic, Matzdorff, Axel, Stahl, Michael Konrad, Schepp, Wolfgang, Burk, Martin, Mueller, Lothar, Folprecht, Gunnar, Geissler, Michael, Mantovani-Loeffler, Luisa, Hoehler, Thomas, Asperger, Walter, Kroening, Hendrik, von Weikersthal, Ludwig Fischer, Fuxius, Stefan, Groschek, Matthias, Meiler, Johannes, Trarbach, Tanja, Rauh, Jacqueline, Ziegenhagen, Nicolas, Kretzschmar, Albrecht, Graeven, Ullrich, Nusch, Arnd, von Wichert, Goetz, Hofheinz, Ralf-Dieter, Kleber, Gerhard, Schmidt, Karl-Heinz, Vehling-Kaiser, Ursula, Baum, Claudia, Schuette, Jochen, Haag, Georg Martin, Holtkamp, Wilhelm, Potenberg, Jochen, Reiber, Tobias, Schliesser, Georg, Schmoll, Hans-Joachim, Schneider-Kappus, Wolfgang, Abenhardt, Wolfgang, Denzlinger, Claudio, Henning, Jan, Marxsen, Bartscht, Derigs, Hans Guenter, Lambertz, Helmut, Becker-Boost, Ingulf, Caca, Karel, Constantin, Christian, Decker, Thomas, Eschenburg, Henning, Gabius, Sigrun, Hebart, Holger, Hoffmeister, Albrecht, Horst, Heinz-August, Kremers, Stephan, Leithaeuser, Malte, Mueller, Sebastian, Wagner, Siegfried, Daum, Severin, Schlegel, Frank, Stauch, Martina, Heinemann, Volker, Maiello, Evaristo, Latini, Luciano, Zaniboni, Alberto, Amadori, Dino, Aprile, Giuseppe, Barni, Sandro, Mattioli, Rodolfo, Martoni, Andrea, Passalacqua, Rodolfo, Nicolini, Mario, Pasquini, Enzo, Rabbi, Carla, Aitini, Enrico, Ravaioli, Alberto, Barone, Carlo, Biasco, Guido, Tamberi, Stefano, Gambi, Angelo, Verusio, Claudio, Marzola, Marina, Lelli, Giorgio, Boni, Corrado, Cascinu, Stefano, Bidoli, Paolo, Vaghi, Massimo, Cruciani, Giorgio, Di Costanzo, Francesco, Sobrero, Alberto, Mini, Enrico, Petrioli, Roberto, Aglietta, Massimo, Alabiso, Oscar, Capuzzo, Federico, Falcone, Alfredo, Corsi, Domenico Cristi, Labianca, Roberto, Salvagni, Stefania, Chiara, Silvana, Ciuffreda, Libero, Ferraù, Francesco, Giuliani, Francesco, Lonardi, Sara, Gebbia, Nicola, Mantovani, Giovanni, Sanches, Evaristo, Mellidez, Juan Carlos, Santos, Pedro, Freire, Joao, Sarmento, Cristina, Costa, Luis, Pinto, Antonio Moreira, Barroso, Sergio, Santo, Jorge Espirito, Guedes, Fátima, Monteiro, Amélia, Sa, Anabela, Furtado, Irene, Salazar, Ramon, Aguilar, Enrique Aranda, Herrero, Fernando Rivera, Tabernero, Josep, Valera, Javier Sastre, Ayerbes, Manuel Valladares, Batlle, Jaime Feliu, Gil, Silvia, Esteve, Albert Abad, Garcia-Giron, Carlos, Vivanco, Guillermo Lopez, Salvia, Antonia Salud, Orduña, Vicente Alonso, Garcia, Ruth Vera, Gallego, Javier, Sureda, Bartomeu Massuti, Remon, Jordi, Safont Aguilera, Maria Jose, Nogueras, Luis Cirera, Merino, Bernado Queralt, Castro, Cristina Gravalos, de Prado, Purificacion Martinez, Pericay, Carlos Pijaume, Figueiras, Manuel Constenla, Jordan, Inmaculada Guasch, Gome Reina, Maria Jose, Garcia, Amelia Lopez-Ladron, Garcia-Ramos, Antonio Arrivi, Cervantes, Andres, Martos, Carlos Fernandez, Gaspar, Eugenio Marcuello, Montero, Ines Cabezas, Emperador, Pilar Escudero, Carbonero, Ana Leon, Castillo, Manuel Gallen, Garcia, Teresa Garcia, Lopez, Jose Garcia, Flores, Encarnacion Gonzalez, Morales, Monica Guillot, Muñoz, Marta Llanos, Martín, Ana López, Maurel, Joan, Camara, Juan Carlos, Garcia, Rosario Dueñas, Salgado, Mercedes, Busquier, Isabel Hernandez, Ruiz, Teresa Checa, Muñoa, Adelaida Lacasta, Aliguer, Miquel Nogue, de Taranco, Amalia Velasco Ortiz, Ureña, Miguel Mendez, Gaspa, Ferran Losa, Ponce, Jose Juan, Roig, Carlos Bosch, Jimenez, Pedro Valero, Brotons, Antonio Galan, Rodriguez, Santiago Albiol, Martinez, Jose Ales, Ruiz, Liliana Canosa, Ruiz, Margarita Centelles, Bridgewater, John, Glynne-Jones, Rob, Tahir, Saad, Hickish, Tamas, Cassidy, Jim, Samuel, Leslie, Emile, Jean-François, Julié, Catherine, Le Malicot, Karine, Lepage, Come, Dimet, Stéphanie, Boulagnon-Rombi, Camille, Allard, Marc-Antoine, Penault-Llorca, Frédérique, Bennouna, Jaafar, and Laurent-Puig, Pierre

Published
2017
Full Text
View/download PDF

37. S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus.

Author

Ebert, Matthias P., Fischbach, Wolfgang, Hollerbach, Stephan, Höppner, Jens, Lorenz, Dietmar, Stahl, Michael, Stuschke, Martin, Pech, Oliver, Vanhoefer, Udo, Porschen, Rainer, Baretton, Gustavo, Bostel, Tilmann, Bruns, Christiane, Ell, Christian, Follmann, Markus, Goerling, Ute, Grenacher, Lars, Haardt, Julia, Hölscher, Arnulf H., and Hummel, Richard

Published
2024
Full Text
View/download PDF

42. Updated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus

Author

Porschen, Rainer, Fischbach, Wolfgang, Gockel, Ines, Hollerbach, Stephan, Hölscher, Arnulf, Jansen, Petra Lynen, Miehlke, Stephan, Pech, Oliver, Stahl, Michael, Vanhoefer, Udo, and Ebert, Matthias P. A.

Abstract

Diagnosis and therapy of esophageal carcinoma is challenging and requires a multidisciplinary approach. The purpose of the updated German guideline “Diagnosis and Treatment of Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus—version 3.1” is to provide practical and evidence‐based advice for the management of patients with esophageal cancer. Recommendations were developed by a multidisciplinary expert panel based on an extensive and systematic evaluation of the published medical literature and the application of well‐established methodologies (e.g. Oxford evidence grading scheme, grading of recommendations). Accurate diagnostic evaluation of the primary tumor as well as lymph node and distant metastases is required in order to guide patients to a stage‐appropriate therapy after the initial diagnosis of esophageal cancer. In high‐grade intraepithelial neoplasia or mucosal carcinoma endoscopic resection shall be performed. Whether endoscopic resection is the definitive therapeutic measure depends on the histopathological evaluation of the resection specimen. Esophagectomy should be performed minimally invasive or in combination with open procedures (hybrid technique). Because the prognosis in locally advanced esophageal carcinoma is poor with surgery alone, multimodality therapy is recommended. In locally advanced adenocarcinomas of the esophagus or esophagogastric junction, perioperative chemotherapy or preoperative radiochemotherapy should be administered. In locally advanced squamous cell carcinomas of the esophagus, preoperative radiochemotherapy followed by complete resection or definitive radiochemotherapy without surgery should be performed. In the case of residual tumor in the resection specimen after neoadjuvant radiochemotherapy and R0 resection of squamous cell carcinoma or adenocarcinoma, adjuvant immunotherapy with nivolumab should be given. Systemic palliative treatment options (chemotherapy, chemotherapy plus immunotherapy, immunotherapy alone) in unresectable or metastastic esophageal cancer depend on histology and are stratified according to PD‐L1 and/or Her2 expression.

Published
2024
Full Text
View/download PDF

43. RENAISSANCE at LAST.

Author

Stahl, Michael

Subjects
MOTORSPORTS, LUXURY cars, SPORTS cars, BRAND image, BOND, James (Fictional character), BILLIONAIRES
Abstract

The article discusses Lawrence Stroll's involvement with Aston Martin, including his ownership of the Formula 1 team and the luxury car brand. Stroll's vision for the brand includes creating the world's most desirable luxury brand and building a successful Formula 1 team. Despite Stroll's efforts, Aston Martin's financial performance has not matched the excitement around its products and racing successes, with its share price declining significantly. The article also highlights the history and challenges faced by Aston Martin as a luxury carmaker. [Extracted from the article]

Published
2024

44. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma

Author

Faron, Matthieu, Cheugoua-Zanetsie, Maurice, Tierney, Jayne, Thirion, Pierre, Nankivell, Matthew, Winter, Kathryn, Yang, Hong, Shapiro, Joel, Vernerey, Dewi, Smithers, B. Mark, Walsh, Thomas, Piessen, Guillaume, Nilsson, Magnus, Boonstra, Jurjen, Ychou, Marc, Law, Simon, Cunningham, David, de Vathaire, Florent, Stahl, Michael, Urba, Susan, Valmasoni, Michele, Williaume, Danièle, Thomas, Janine, Lordick, Florian, Tepper, Joel, Roth, Jack, Gebski, Val, Burmeister, Bryan, Paoletti, Xavier, van Sandick, Johanna, Fu, Jianhua, Pignon, Jean Pierre, Ducreux, Michel, Michiels, Stefan, Faron, Matthieu, Cheugoua-Zanetsie, Maurice, Tierney, Jayne, Thirion, Pierre, Nankivell, Matthew, Winter, Kathryn, Yang, Hong, Shapiro, Joel, Vernerey, Dewi, Smithers, B. Mark, Walsh, Thomas, Piessen, Guillaume, Nilsson, Magnus, Boonstra, Jurjen, Ychou, Marc, Law, Simon, Cunningham, David, de Vathaire, Florent, Stahl, Michael, Urba, Susan, Valmasoni, Michele, Williaume, Danièle, Thomas, Janine, Lordick, Florian, Tepper, Joel, Roth, Jack, Gebski, Val, Burmeister, Bryan, Paoletti, Xavier, van Sandick, Johanna, Fu, Jianhua, Pignon, Jean Pierre, Ducreux, Michel, and Michiels, Stefan

Abstract

PURPOSE: The optimal neoadjuvant treatment for resectable carcinoma of the thoracic esophagus (TE) or gastroesophageal junction (GEJ) remains a matter of debate. We performed an individual participant data (IPD) network meta-analysis (NMA) of randomized controlled trials (RCTs) to study the effect of chemotherapy or chemoradiotherapy, with a focus on tumor location and histology subgroups. PATIENTS AND METHODS: All, published or unpublished, RCTs closed to accrual before December 31, 2015 and having compared at least two of the following strategies were eligible: upfront surgery (S), chemotherapy followed by surgery (CS), and chemoradiotherapy followed by surgery (CRS). All analyses were conducted on IPD obtained from investigators. The primary end point was overall survival (OS). The IPD-NMA was analyzed by a one-step mixed-effect Cox model adjusted for age, sex, tumor location, and histology. The NMA was registered in PROSPERO (CRD42018107158). RESULTS: IPD were obtained for 26 of 35 RCTs (4,985 of 5,807 patients) corresponding to 12 comparisons for CS-S, 12 for CRS-S, and four for CRS-CS. CS and CRS led to increased OS when compared with S with hazard ratio (HR) = 0.86 (0.75 to 0.99), P = .03 and HR = 0.77 (0.68 to 0.87), P < .001 respectively. The NMA comparison of CRS versus CS for OS gave a HR of 0.90 (0.74 to 1.09), P = .27 (consistency P = .26, heterogeneity P = .0038). For CS versus S, a larger effect on OS was observed for GEJ versus TE tumors (P = .036). For the CRS versus S and CRS versus CS, a larger effect on OS was observed for women (P = .003, .012, respectively). CONCLUSION:Neoadjuvant chemotherapy and chemoradiotherapy were consistently better than S alone across histology, but with some variation in the magnitude of treatment effect by sex for CRS and tumor location for CS. A strong OS difference between CS and CRS was not identified.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results